Is RGEN a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

494 people get RGEN articles and Market Currents by email alert.

Get email alerts on RGEN »

HEADLINES:

SmithOnStocks Opines On Recent Biotech News
Smith On Stocks • Mon, May 13 • 8 Comments
Repligen's CEO Discusses Q1 2013 Results - Earnings Call Transcript
Fri, May 3
Repligen Reports First Quarter 2013 Financial Results

GlobeNewswire (May 2, 2013)
Repligen to Report First Quarter 2013 Financial Results

GlobeNewswire (Apr 23, 2013)
Repligen Promises To Be A Cash Flow Machine
Smith On Stocks • Tue, Apr 2 • 6 Comments
Repligen Management Discusses Q4 2012 Results - Earnings Call Transcript
Thu, Mar 7
Repligen Reports Fourth Quarter and Full Year 2012 Financial Results and Provides Financial Guidance for 2013

GlobeNewswire (Mar 7, 2013)
Repligen to Report Fourth Quarter and Full Year 2012 Financial Results

GlobeNewswire (Mar 1, 2013)
Warren Isabelle: 2013 Will Be A Stock Picker's Market
Joseph Allen • Mon, Jan 14
Repligen Announces Licensing Agreement with Pfizer for Spinal Muscular Atrophy Program

Business Wire (Jan 3, 2013)
Repligen Is A Buy: You Don't Have To Mine Gold To Make Money In A Gold Rush
Smith On Stocks • Wed, Dec 5, 2012 • 14 Comments
Repligen Management Discusses Q3 2012 Results - Earnings Call Transcript
Thu, Nov 8, 2012
Repligen Reports Third Quarter 2012 Financial Results

Business Wire (Nov 8, 2012)
Repligen CEO to Present at Upcoming Investor Conferences

Business Wire (Nov 7, 2012)
Repligen To Report Third Quarter of 2012 Financial Results

Business Wire (Oct 26, 2012)
Top 5 Stocks With Insider Buys Filed On September 24 To Consider
Markus Aarnio • Tue, Sep 25, 2012
3 Medical Growth Stocks Nearing All-Time Highs
Joshua Hayes • Mon, Sep 24, 2012 • 1 Comment
Repligen Appoints Jonathan I. Lieber as CFO

Business Wire (Sep 21, 2012)
Repligen to Present at Stifel Nicolaus Healthcare Conference 2012

Business Wire (Aug 29, 2012)
Repligen Management Discusses Q2 2012 Results - Earnings Call Transcript
Thu, Aug 2, 2012

To learn more about Seeking Alpha Pro, click here.

Repligen Promises To Be A Cash Flow Machine
Smith On Stocks • Tue, Apr 2 • 6 Comments
Repligen Is A Buy: You Don't Have To Mine Gold To Make Money In A Gold Rush
Smith On Stocks • Wed, Dec 5, 2012 • 14 Comments
Repligen: Catalysts For An Easy Double
Bob's Stocks • Wed, Apr 11, 2012 • 2 Comments
Repligen: A Promising Biotech Play
Michael Kudrna • Wed, Jan 26, 2011 • 3 Comments
Repligen's Promising Potential in 2011
M. E. Garza • Thu, Dec 23, 2010
Repligen Jumps on Higher Volume, No News
H.S. Ayoub • Tue, Apr 10, 2007

SmithOnStocks Opines On Recent Biotech News
Smith On Stocks • Mon, May 13 • 8 Comments
Warren Isabelle: 2013 Will Be A Stock Picker's Market
Joseph Allen • Mon, Jan 14
Top 5 Stocks With Insider Buys Filed On September 24 To Consider
Markus Aarnio • Tue, Sep 25, 2012
3 Medical Growth Stocks Nearing All-Time Highs
Joshua Hayes • Mon, Sep 24, 2012 • 1 Comment
5 Cash-Heavy Biotechs That Analysts Favor
ZetaKap • Sun, Jul 15, 2012 • 3 Comments
Russell 3000 U.S. Healthcare Additions For June 2012
EXPstocktrader • Mon, Jun 11, 2012 • 2 Comments
13 Healthcare Stocks With Major June Catalysts
Spencer Knight • Sun, Jun 3, 2012 • 10 Comments
Bio-Pharma Catalyst Trades And ASCO Movers: Making The Grade
Scott Matusow • Tue, May 15, 2012 • 21 Comments
Selling An FDA Approval: Recent Results
BinaryLeverage • Wed, May 9, 2012 • 11 Comments
Today's Bio-Pharma Catalyst Trades And ASCO Movers
Scott Matusow • Tue, May 8, 2012 • 15 Comments
6 Biotech Stocks With Huge Potential In June
StockPandit • Thu, May 3, 2012 • 3 Comments
14 Rallying Biotech Stocks Being Snapped Up By Insiders
Kapitall • Thu, Feb 2, 2012 • 1 Comment
20 Biotech Stocks With Strong Corporate Governance
Kapitall • Wed, Oct 5, 2011
5 Healthcare Company Updates Released Wednesday
Alex Shadunsky • Thu, Jul 28, 2011 • 2 Comments
6 Cash Rich Biotech Stocks With Catalysts
Rougemont • Fri, Apr 8, 2011 • 5 Comments
5 Biotechs Investors Should Be Watching
M. E. Garza • Mon, Nov 29, 2010 • 4 Comments
Biotech's Latest Failed Trials, Missed Targets
The Burrill Report • Mon, Dec 14, 2009 • 2 Comments
Smallcaps Finish Down 3+% for July; M-Systems Up After Acquisition by SanDisk
SA Editor Jonathan Liss • Tue, Aug 1, 2006

Repligen's CEO Discusses Q1 2013 Results - Earnings Call Transcript
Fri, May 3
Repligen Management Discusses Q4 2012 Results - Earnings Call Transcript
Thu, Mar 7
Repligen Management Discusses Q3 2012 Results - Earnings Call Transcript
Thu, Nov 8, 2012
Repligen Management Discusses Q2 2012 Results - Earnings Call Transcript
Thu, Aug 2, 2012
Repligen Corporation F3Q10 (Qtr End 12/31/09) Earnings Call Transcript
Thu, Feb 4, 2010
Repligen Corp. F2Q09 (Qtr. End 09/30/09) Earnings Call Transcript
Thu, Nov 5, 2009
Repligen Corporation F3Q09 (Qtr End 12/31/08) Earnings Call Transcript
Wed, Feb 11, 2009
Repligen Corporation F2Q09 (Qtr End 09/30/08) Earnings Call Transcript
Mon, Nov 24, 2008
Repligen Corporation Q1 2009 Earnings Call Transcript
Thu, Aug 7, 2008
Repligen Corporation F4Q08 (Qtr End 03/31/2008) Earnings Call Transcript
Sat, Jun 14, 2008

Repligen Reports First Quarter 2013 Financial Results

GlobeNewswire (May 2, 2013)
Repligen to Report First Quarter 2013 Financial Results

GlobeNewswire (Apr 23, 2013)
Repligen Reports Fourth Quarter and Full Year 2012 Financial Results and Provides Financial Guidance for 2013

GlobeNewswire (Mar 7, 2013)
Repligen to Report Fourth Quarter and Full Year 2012 Financial Results

GlobeNewswire (Mar 1, 2013)
Repligen Announces Licensing Agreement with Pfizer for Spinal Muscular Atrophy Program

Business Wire (Jan 3, 2013)
Repligen Reports Third Quarter 2012 Financial Results

Business Wire (Nov 8, 2012)
Repligen CEO to Present at Upcoming Investor Conferences

Business Wire (Nov 7, 2012)
Repligen To Report Third Quarter of 2012 Financial Results

Business Wire (Oct 26, 2012)
Repligen Appoints Jonathan I. Lieber as CFO

Business Wire (Sep 21, 2012)
Repligen to Present at Stifel Nicolaus Healthcare Conference 2012

Business Wire (Aug 29, 2012)
Repligen Announces Strategic Focus on Bioprocessing Business and Reports Second Quarter 2012 Financial Results

Business Wire (Aug 2, 2012)
Repligen To Report Second Quarter of 2012 Financial Results

Business Wire (Jul 24, 2012)
Repligen to Present at JMP Securities Healthcare Conference 2012

Business Wire (Jul 6, 2012)
Repligen Added to the Russell 2000 Index

Business Wire (Jun 25, 2012)
Movers & Shakers: Friday’s biggest gaining and declining stocks

at MarketWatch.com (Jun 22, 2012)
Stocks to Watch: FB, FDO, CCL & More

at CNBC.com (Jun 22, 2012)
Repligen Receives Complete Response Letter from FDA for RG1068 NDA

Business Wire (Jun 22, 2012)
Repligen To Present at Jefferies 2012 Global Healthcare Conference

Business Wire (May 30, 2012)
Repligen Announces Support of Amended Stockholder Proposal

Business Wire (May 7, 2012)
Repligen Reports First Quarter 2012 Financial Results; Conference Call at 8:30 a.m. Today

Business Wire (May 3, 2012)

RGEN vs. ETF Alternatives

Company Description

Currently, there's no company description for RGEN.

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, March 7, 11:04 AM Repligen (RGEN -0.5%) slips after its Q4 EPS misses estimates. Revenue jumped 160% Y/Y however, led by strength in its bioprocessing business and higher royalty revenue from Bristol-Myers Squibb (BMY) and Pfizer (PFE). looking forward, the company see FY13 net income coming in around $18M - $20M. 1 Comment [Healthcare, Earnings]
Thursday, March 7, 7:37 AM Repligen (RGEN): Q4 EPS of $0.30. Revenue of $18.8M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Friday, June 22, 2012, 8:58 AM Repligen (RGEN) -20.3% premarket after the FDA confirms the biotech company must conduct further trials before potentially getting approval for its RG1068 synthetic human secretin used to detect pancreatic-duct abnormalities in patients with pancreatitis. Comment! [Healthcare, On the Move]
Monday, April 30, 2012, 11:44 AM Repligen (RGEN -0.3%) shareholder Ronald L. Chez says that after speaking to Board Chairperson Karen Dawes, he plans to call as special meeting to discuss reducing the number of shares outstanding in the company and other strategic alternatives for the company on the back of recent developments in its new drug application for RG1068. 1 Comment [Healthcare]
Thursday, April 26, 2012, 11:12 AM Shares of Repligen (RGEN -40.4%) get hammered after the FDA cancels an advisory-committee meeting to review the company's new-drug application for its pancreatitis drug RG1068. The drug developer says it expects the FDA to request additional clinical-trial data. 1 Comment [Healthcare, On the Move]
Tuesday, February 21, 2012, 8:59 AM The FDA grants priority review for Repligen's (RGEN) SecreFlo product used to help detect pancreatic cancer in MRIs. If approved, the firm estimates 300K MRI procedures a year could use the noninvasive method of evaluating patients. Shares +9.2% premarket. 1 Comment [On the Move, Healthcare]
Wednesday, December 21, 2011, 8:10 AM Repligen (RGEN) announces the submission of a New Drug Application for SecreFlo, including a request to receive priority review by the FDA. The firm says it plans to release initial results from a study on the ability of SecreFlo to detect pancreatic cancer in the first half of 2012. Comment! [Healthcare]
Thursday, June 23, 2011, 4:17 PM Repligen's (RGEN +5%) jumps after its spinal muscular atrophy drug gets a fast-track designation from the FDA, and a postive opinion for orphan status from the European Medicines Agency. Comment! [Healthcare]
Monday, March 7, 2011, 9:05 AM Premarket gainers: TOMO +23%. JRCC +12%. RAME +12%. STX +11%. WDC +11%. AVL +7%. QTM +7%. EXK +7%. DPTR +6%. SSN +6%. SVVS +6%. GPL +5%. PZG +4%. SHZ +4%. OCZ +4%. GMXR +4%. VLNC +4%. MCP +4%. ICO +4%. BQI +4%. SVM +3%. SLW +3%. PHYS +3%.
Losers: RGEN -25%. CTIC -8%. ARAY -7%. CIEN -4%. JOE -3%. Comment!

ZetaKap
5 Cash-Heavy Biotechs That Analysts Favor http://bit.ly/OH4V09 $CRTX $IMMU $OPTR $RGEN $SHP @ZetaKap
7/15/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

timtrading
bought $RGEN at 6.52, stop loss 6.47 - http://bit.ly/IbglMp
4/25/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

freefdawatchlist
Check out upcoming Fda approval Dates http://bit.ly/H6kqQR $ARNA, $RGEN, $XNPT, $SLXP, $GILD, $ALXA, $PLX,$VVUS, $AMGN,$FURX,$CTIC,$VRTX
4/1/12
Reply (3)

• !Report Abuse
View all 3 replies
freefdawatchlist: don't buy more, because if fda delay it by 3 month, the stock may drop. Check out other stock which haven't rallied up till now.
4/1/12
• !Report Abuse
phemale60: VVUS's Avanafil up for FDA approval late April also. Any info about it? I appreciate your insight!
4/1/12
• !Report Abuse
Add a reply...

140 characters

Joshua Hayes
new instablog: Rally Attempt Begins with Two Days of Gains. Medical stocks are our leaders. VRUS ELN JAZZ STAA ALXN BIIB RGEN MAKO OSUR BMY
10/5/11
Reply (1)

• !Report Abuse
View all 1 replies
cowpieTX: i manage a diagnostic imaging center for a 17b market cap company. the cuts are real and they are deep. tread carefully.
10/5/11
• !Report Abuse
Add a reply...

140 characters

Michael Kudrna
Reduced position in $RGEN and letting profits ride into earnings next week. Dont like holding big positions into earnings. Near Resistance
4/15/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Michael Kudrna
Select Biotechs still acting healthy in this market. $RGEN and $EXEL doing a little shake and bake action
4/14/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Michael Kudrna
$RGEN catching low volume bids, biotech acting as safe haven during market pullback
4/12/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Michael Kudrna
$RGEN should have a fairly clear path for a slow move towards $4.30-4.40 resistance levels (moving averages)
4/8/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Michael Kudrna
$RGEN moving closer to key psychological resistance level at $4.
4/7/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Michael Kudrna
L2 for $RGEN shows exactly what we want to see in an accumulation phase. Likely need to stay patient though as they are not paying up yet
3/17/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

freefdawatchlist
Check out upcoming Fda approval Dates http://bit.ly/H6kqQR $ARNA, $RGEN, $XNPT, $SLXP, $GILD, $ALXA, $PLX,$VVUS, $AMGN,$FURX,$CTIC,$VRTX
4/1/12
Reply (3)

• !Report Abuse
View all 3 replies
freefdawatchlist: don't buy more, because if fda delay it by 3 month, the stock may drop. Check out other stock which haven't rallied up till now.
4/1/12
• !Report Abuse
phemale60: VVUS's Avanafil up for FDA approval late April also. Any info about it? I appreciate your insight!
4/1/12
• !Report Abuse
Add a reply...

140 characters

Joshua Hayes
new instablog: Rally Attempt Begins with Two Days of Gains. Medical stocks are our leaders. VRUS ELN JAZZ STAA ALXN BIIB RGEN MAKO OSUR BMY
10/5/11
Reply (1)

• !Report Abuse
View all 1 replies
cowpieTX: i manage a diagnostic imaging center for a 17b market cap company. the cuts are real and they are deep. tread carefully.
10/5/11
• !Report Abuse
Add a reply...

140 characters

RGEN Repligen Corporation

RGEN

Repligen Corporation